HOME >> BIOLOGY >> NEWS
New milestones on the path to conquering HIV drug resistance (AIDS)

NEW BRUNSWICK/PISCATAWAY, N.J. HIV is a moving target, unpredictably changing direction to elude anti-AIDS drugs, but researchers at Rutgers are clearly on the track of solutions to combat HIV drug resistance. Leading a multidisciplinary ensemble of colleagues, Rutgers Chemistry Professor Eddy Arnold recently reported on studies that revealed how some drugs may be getting the better of the virus' molecular defenses.

Reports in the May issues of Nature Structural & Molecular Biology and the Journal of Medicinal Chemistry propose answers to why it is relatively difficult for the AIDS virus to develop resistance to the drug, tenofovir, or the DAPY (diarylpyrimidine) family of compounds, and offers explanations of the mechanisms involved.

Tenofovir and the DAPY compounds are different types of reverse transcriptase (RT) inhibitors. RT is the enzyme or molecular machine the AIDS virus uses to replicate its genetic material. The two life-saving drugs approach the problem of drug resistance in different ways.

Arnold and his colleagues work on drugs that target HIV RT. "We try to understand how these drugs work and how they may be able to evade resistance mechanisms so that we can apply the information to the design of better drugs," said Arnold, a resident faculty member of the Center for Advanced Biotechnology and Medicine. The research institute is jointly administered by the University of Medicine and Dentistry of New Jersey and Rutgers, The State University of New Jersey.

Since 1987, Arnold has collaborated with Stephen Hughes of the National Cancer Institute's Cancer Research and Development Center at Frederick, Md., constituting what Arnold calls "an inseparable team." Hughes is providing the biochemical analysis of the problem in conjunction with Arnold's X-ray crystallography a method by which X-ray diffraction patterns obtained from crystals are used to map the three-dimensional atomic structure of large molecules.

"W
'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 x652
Rutgers, the State University of New Jersey
29-Jun-2004


Page: 1 2 3

Related biology news :

1. New reserach shows promise in conquering ulcer-causing H. pylori
2. Master of antimalarial resistance
3. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
4. Evolvability could be a driving force in drug resistance
5. Insecticide resistance: A constraint on evolutionary change
6. New drug shows promise against Gleevec resistance in mice
7. Study investigates breast cancer resistance to tamoxifen and possible way to reverse it
8. Antibiotic resistance risk from triclosan questioned
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Researchers string together players in pesticide resistance orchestra
11. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New milestones the path conquering HIV drug resistance AIDS

(Date:7/2/2015)... , June 25, 2015 ... the addition of the "Natural Language Processing ... (Recognition, IVR, OCR, Pattern & Image Recognition) - ... offering. The key vendors occupying the ... IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
(Date:8/3/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will webcast ... 2015 on Monday, August 10, 2015 at 4:30 p.m. ... and chief executive officer, will lead the call. On ... for the second quarter 2015. The call ... Halozyme,s corporate website and a recording will be made ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... is processed to get such derivatives as ethylbenzene, a precursor to styrene, used ... within the automotive industry for the production of tyres and other components. Thus, ...
(Date:8/3/2015)... , August 3, 2015 E-QURE ... commercialization of its Bio-electrical Signal Therapy device ("BST Device"), ... of hard to heal chronic wounds, today announced that ... Chemipal, an Israeli distributor specializing in medical devices, for ... Chemipal is a 70 years old, sales, marketing ...
(Date:8/3/2015)... ... 03, 2015 , ... Sterlitech Corporation introduces the compact, quiet, ... analytical laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an oil-free ... maintenance-free solution for a broad range of vacuum filtration applications. , Featuring a ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Sterlitech Launches New Line of Vacuum Pumps 2
Cached News: